-
Part 2 | Session 1 Late-Breaker Discussion: The EMPACT-MI Trial
-
Part 2 | Session 2 Late-Breaker Discussion: The AEGIS-II Trial
-
Part 2 | Session 3 Late-Breaker Discussion: The RELIEVE-HF Trial
-
Part 2 | Session 4 Late-Breaker Discussion: The ARISE-HF Trial
-
Part 3 | Session 2 Zilbesiran in Patients With Hypertension: KARDIA-2
-
Part 3 | Session 5 Chelation Therapy in Post-MI Pts with Diabetes: TACT2
-
Part 3 | Session 6 Semaglutide in Patients with HfpEF, Obesity and Diabetes: STEP HFpEF
-
Part 3 | Session 7 Self-Expanding vs Balloon Expandable TAVR: The SMART Trial
-
Part 3 | Session 9 Technology-Assisted Nonprescription Rosuvastatin: TACTiC
-
Part 3 | Session 10 Coronary Sinus Reducer in Refractory Angina: ORBITA COSMIC
-
Part 3 | Session 11 TAVI Vs SAVR in Patients with Severe Aortic Valve Stenosis: DEDICATE-DZHK6
-
Part 4 | Session 1 Artificial Intelligence in Cardiology: What You Need to Know in 2024
-
Part 4 | Session 2 Weight Loss Medications: What You Need to Know in 2024
-
Part 5 | Session 2 New Frontiers in Medicine & Focusing your Efforts
-
Part 5 | Session 3 Enhancing Patient Care & How to Get Involved with Clinical Research
-
Part 1 | Session 1 ACC.24 Late-breaking Science Wrap Up
Our recurring review series, View from the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offers a thorough examination of late-breaking and featured scientific findings, highlighting significant data.
To delve deeper into the pivotal clinical trial data unveiled at ACC 24, Dr Harriette Van Spall (McMaster University, Hamilton, CA) conducts interviews with the principal investigators as part of her Late-Breaker Discussion Series.
For brief and focused coverage of the essential data unveiled, our accessible Expert Interviews were conducted with a select group of faculty members, concentrating on the results, relevance, and implications for future research.
Watch our Behind the Heart series to learn more the personal perspectives from the investigators behind top trials in cardiovascular science.
More from this programme
Part 1
View from the Thoraxcenter
In these concise episodes of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their thoughts on the top late-breaking trials that will be presented at ACC.24.
Part 2
Late-Breaker Discussion Series
Host, Dr Harriette Van Spall is joined by principal investigators for discussion on selected late-breaking trials.
Part 3
Expert Interviews
Expert Interviews conducted with a select group of faculty members, concentrating on the results, relevance, and implications for future research.
Part 4
Highlights
Part 5
Behind the Heart
Watch our Behind the Heart series to learn more the personal perspectives from the investigators behind top trials in cardiovascular science.
Faculty Biographies
Nicolas M Van Mieghem
Full Professor of Interventional Cardiology
Prof Van Mieghem initially intended to train as a cardiac surgeon but decided to specialise in interventional cardiology instead, following advice from a mentor. This decision was cemented when he read the first-in-human case report of transcatheter aortic valve implantation (TAVI) in Circulation by Alain Cribier in 2002. Prof Van Mieghem believes that great cardiologist genuinely cares for their patients. He names Gary Roubin, Dr Manu Malbrain and Professor Patrick Serruys among his mentors.
Academic History
Prof. Nicolas M. Van Mieghem completed his medical training at the Catholic University of Leuven (Belgium), where he earned both his medical degree and his specialist degree in cardiology. During his time in Leuven, he developed a strong interest in cardiovascular medicine, particularly in the emerging field of minimally invasive cardiac interventions. After finishing his core medical and cardiology training, he pursued multiple advanced…
Joost Daemen
Interventional Cardiologist
Dr Joost Daemen, MD, PhD is a senior interventional cardiologist at the Thorax Center, Erasmus MC, Rotterdam, NL. Dr Daemen obtained his degree in medicine at the Erasmus University Medical Center, Rotterdam in 2005 and did 2 years of internal medicine training and 4 years of general cardiology training at the Thoraxcenter, Rotterdam.
Dr Daemen is actively involved in several drug-eluting stent trials and is Principal Investigator of four trials focusing on the safety and efficacy of renal sympathetic denervation in hypertension, heart failure, vasospastic angina and heart failure. Dr Daemen is a member of the editorial board of EuroIntervention and the Netherlands Heart Journal, member of Young ICIN, and has completed courses in biomedical statistics and device training.
Comments